surmount-1 tirzepatide weight loss percent 72 weeks SURMOUNT-2: confers about 15% in adults with obesity and diabetes Gastrointestinal tolerability and weight reduction
Description
Plateaus are common and usually reflect metabolic adaptation, not loss of drug effect
If additional glycemic control is needed, increase the dosage in 2.5 mg increments after at least 4 weeks on the current dose
Its strongest feature is flat-rate pricing that does not climb as your dose increases
The results of this particular clinician trial and some others have proven that tirzepatide is very effective for weight loss
